Further exploratory analysis of the tissue from this trial (i.e. comparisons of genome-wide mRNA expression data between groups) may help determine key components of the Hedgehog pathway in clinically localized prostate cancer and suggest opportunities for combination of Smo antagonists with other systemic therapies. The gene discussed is SMO; the disease is prostate cancer.